Q32 Bio Inc. entered into a Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co. on March 27, 2026. The agreement allows the company to offer and sell shares of its common stock with an aggregate offering price of up to $14,200,000. Sales will be made from time to time at the company's sole discretion through Cantor Fitzgerald & Co. as the sales agent. The company will pay the sales agent a cash commission of 3.0% of the gross proceeds from the sale of shares. The offering is pursuant to the company's shelf registration statement on Form S-3 (File No. 333-286491), which was declared effective by the SEC on April 21, 2025. The company is not obligated to sell any shares under the agreement, and either party may suspend or terminate the offering.